Skip to main content
Top
Published in: Hormones 4/2021

01-12-2021 | Panhypopituitarism | Teaching Case Presentations

Two challenging cases of pituicytoma

Authors: Hatice Ozisik, Banu Sarer Yurekli, Ilgın Yildirim Simsir, Yesim Ertan, Cenk Eraslan, Nilufer Ozdemir, Erkin Ozgiray, Fusun Saygili

Published in: Hormones | Issue 4/2021

Login to get access

Abstract

Introduction

Pituicytoma is a rare tumor of the pituitary gland derived from neurohypophyseal pituicytes.

Case 1

A 58-year-old female presented with decreased vision; she was admitted to the neurosurgery department of Ege University after the detection of a pituitary macroadenoma. Magnetic resonance imaging (MRI) showed a 28 * 18 * 17-mm suprasellar mass, and laboratory tests revealed hypopituitarism. Hydrocortisone and L-thyroxine treatment were initiated, and the patient underwent resection through the endoscopic endonasal approach (EEA). The histopathological examination revealed a pituicytoma. The recurrence of tumor was detected during the 1-year follow-up, and the patient is awaiting surgery.

Case 2

A 70-year-old woman presented with visual changes; she had a past medical history of hypophyseal macroadenoma and pituicytoma resected through an EEA in 2012 and 2017, respectively. During follow-up, 2 years after the second surgery, MRI showed progression of the pituicytoma then measuring 38 × 23 × 22 mm; it had invaded the cavernous sinus and was causing hydrocephaly and panhypopituitarism. The patient underwent the third resection through the transcranial approach in order to minimize bleeding. After this surgery, the patient developed diabetes insipidus and underwent treatment with desmopressin. Histopathological examination revealed a pituicytoma. At 6-month follow-up, imaging showed a sellar suprasellar mass 37 × 22 × 24 mm invading the cavernous sinus, indicative of recurrence. In the postoperative period, the patient applied to the department of radiation oncology to have fractionated radiotherapy.

Discussion

Pituicytomas are known to be low-grade tumors; because of their rarity, they are a real challenge. These patients should be followed up closely.
Literature
1.
go back to reference Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization Classification of Tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRef Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al (2016) The 2016 World Health Organization Classification of Tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRef
2.
go back to reference Asa SL, Mete O (2019) Hypothalamic endocrine tumors: an update. J Clin Med 8(10):1741CrossRef Asa SL, Mete O (2019) Hypothalamic endocrine tumors: an update. J Clin Med 8(10):1741CrossRef
3.
go back to reference Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas NK (2009) Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker? J Neuropathol Exp Neurol 68(5):482–488CrossRef Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas NK (2009) Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker? J Neuropathol Exp Neurol 68(5):482–488CrossRef
4.
go back to reference Brat DJ, Scheithauer BW, Staugaitis SM, Holtzman RN, Morgello S, Burger PC (2000) Pituicytoma: a distinctive low-grade glioma of the neurohypophysis. Am J Surg Pathol 24(3):362–368CrossRef Brat DJ, Scheithauer BW, Staugaitis SM, Holtzman RN, Morgello S, Burger PC (2000) Pituicytoma: a distinctive low-grade glioma of the neurohypophysis. Am J Surg Pathol 24(3):362–368CrossRef
5.
go back to reference Gibbs WN, Monuki ES, Linskey ME, Hasso AN (2006) Pituicytoma: diagnostic features on selective carotid angiography and MR imaging. AJNR Am J Neuroradiol 27(8):1639–1642PubMedPubMedCentral Gibbs WN, Monuki ES, Linskey ME, Hasso AN (2006) Pituicytoma: diagnostic features on selective carotid angiography and MR imaging. AJNR Am J Neuroradiol 27(8):1639–1642PubMedPubMedCentral
6.
go back to reference Lefevre E, Bouazza S, Bielle F, Boch AL (2018) Management of pituicytomas: a multicenter series of eight cases. Pituitary 21(5):507–514CrossRef Lefevre E, Bouazza S, Bielle F, Boch AL (2018) Management of pituicytomas: a multicenter series of eight cases. Pituitary 21(5):507–514CrossRef
7.
go back to reference Mete O, Lopes MB (2017) Overview of the 2017 WHO Classification of pituitary tumors. Endocr Pathol 28(3):228–243CrossRef Mete O, Lopes MB (2017) Overview of the 2017 WHO Classification of pituitary tumors. Endocr Pathol 28(3):228–243CrossRef
8.
go back to reference Vaquero J, Leunda G, Cabezudo JM, Salazar AR, de Miguel J (1981) Granular pituicytomas of the pituitary stalk. Acta Neurochir (Wien) 59(3–4):209–215CrossRef Vaquero J, Leunda G, Cabezudo JM, Salazar AR, de Miguel J (1981) Granular pituicytomas of the pituitary stalk. Acta Neurochir (Wien) 59(3–4):209–215CrossRef
9.
go back to reference Hurley TR, D’Angelo CM, Clasen RA, Wilkinson SB, Passavoy RD (1994) Magnetic resonance imaging and pathological analysis of a pituicytoma: case report. Neurosurgery 35(2):314–317 (discussion 17)CrossRef Hurley TR, D’Angelo CM, Clasen RA, Wilkinson SB, Passavoy RD (1994) Magnetic resonance imaging and pathological analysis of a pituicytoma: case report. Neurosurgery 35(2):314–317 (discussion 17)CrossRef
10.
go back to reference Shah B, Lipper MH, Laws ER, Lopes MB, Spellman MJ (2005) Posterior pituitary astrocytoma: a rare tumor of the neurohypophysis: a case report. AJNR Am J Neuroradiol 26(7):1858–1861PubMedPubMedCentral Shah B, Lipper MH, Laws ER, Lopes MB, Spellman MJ (2005) Posterior pituitary astrocytoma: a rare tumor of the neurohypophysis: a case report. AJNR Am J Neuroradiol 26(7):1858–1861PubMedPubMedCentral
11.
go back to reference Koutourousiou M, Gardner PA, Kofler JK, Fernandez-Miranda JC, Snyderman CH, Lunsford LD (2013) Rare infundibular tumors: clinical presentation, imaging findings, and the role of endoscopic endonasal surgery in their management. J Neurol Surg B Skull Base 74(1):1–11CrossRef Koutourousiou M, Gardner PA, Kofler JK, Fernandez-Miranda JC, Snyderman CH, Lunsford LD (2013) Rare infundibular tumors: clinical presentation, imaging findings, and the role of endoscopic endonasal surgery in their management. J Neurol Surg B Skull Base 74(1):1–11CrossRef
12.
go back to reference Tian Y, Yue S, Jia G, Zhang Y (2013) Childhood giant pituicytoma: a report and review of the literature. Clin Neurol Neurosurg 115(10):1943–1950CrossRef Tian Y, Yue S, Jia G, Zhang Y (2013) Childhood giant pituicytoma: a report and review of the literature. Clin Neurol Neurosurg 115(10):1943–1950CrossRef
13.
go back to reference Neidert MC, Leske H, Burkhardt JK, Kollias SS, Capper D, Schrimpf D et al (2016) Synchronous pituitary adenoma and pituicytoma. Hum Pathol 47(1):138–143CrossRef Neidert MC, Leske H, Burkhardt JK, Kollias SS, Capper D, Schrimpf D et al (2016) Synchronous pituitary adenoma and pituicytoma. Hum Pathol 47(1):138–143CrossRef
14.
go back to reference El Hussein S, Vincentelli C (2017) Pituicytoma: Review of commonalities and distinguishing features among TTF-1 positive tumors of the central nervous system. Ann Diagn Pathol 29:57–61CrossRef El Hussein S, Vincentelli C (2017) Pituicytoma: Review of commonalities and distinguishing features among TTF-1 positive tumors of the central nervous system. Ann Diagn Pathol 29:57–61CrossRef
15.
go back to reference Sahm F, Reuss DE, Giannini C (2018) WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours. Neuropathol Appl Neurobiol 44(2):163–171CrossRef Sahm F, Reuss DE, Giannini C (2018) WHO 2016 classification: changes and advancements in the diagnosis of miscellaneous primary CNS tumours. Neuropathol Appl Neurobiol 44(2):163–171CrossRef
16.
go back to reference Viaene AN, Lee EB, Rosenbaum JN, Nasrallah IM, Nasrallah MP (2019) Histologic, immunohistochemical, and molecular features of pituicytomas and atypical pituicytomas. Acta Neuropathol Commun 7(1):69CrossRef Viaene AN, Lee EB, Rosenbaum JN, Nasrallah IM, Nasrallah MP (2019) Histologic, immunohistochemical, and molecular features of pituicytomas and atypical pituicytomas. Acta Neuropathol Commun 7(1):69CrossRef
17.
go back to reference Pirayesh Islamian A, Buslei R, Saeger W, Fahlbusch R (2012) Pituicytoma: overview of treatment strategies and outcome. Pituitary 15(2):227–236CrossRef Pirayesh Islamian A, Buslei R, Saeger W, Fahlbusch R (2012) Pituicytoma: overview of treatment strategies and outcome. Pituitary 15(2):227–236CrossRef
18.
go back to reference Karamchandani J, Syro LV, Uribe H, Horvath E, Kovacs K (2012) Pituicytoma of the neurohypophysis: analysis of cell proliferation biomarkers. Can J Neurol Sci 39(6):835–837CrossRef Karamchandani J, Syro LV, Uribe H, Horvath E, Kovacs K (2012) Pituicytoma of the neurohypophysis: analysis of cell proliferation biomarkers. Can J Neurol Sci 39(6):835–837CrossRef
19.
go back to reference Mende KC, Matschke J, Burkhardt T, Saeger W, Buslei R, Buchfelder M et al (2017) Pituicytoma-An outlook on possible targeted therapies. CNS Neurosci Ther 23(7):620–626CrossRef Mende KC, Matschke J, Burkhardt T, Saeger W, Buslei R, Buchfelder M et al (2017) Pituicytoma-An outlook on possible targeted therapies. CNS Neurosci Ther 23(7):620–626CrossRef
Metadata
Title
Two challenging cases of pituicytoma
Authors
Hatice Ozisik
Banu Sarer Yurekli
Ilgın Yildirim Simsir
Yesim Ertan
Cenk Eraslan
Nilufer Ozdemir
Erkin Ozgiray
Fusun Saygili
Publication date
01-12-2021
Publisher
Springer International Publishing
Published in
Hormones / Issue 4/2021
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI
https://doi.org/10.1007/s42000-021-00301-6

Other articles of this Issue 4/2021

Hormones 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine